We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Ask ADVFN Intelligence (AI)
Teva to Present at the Jefferies London Healthcare Conference TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that...
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted...
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition IMPACT-TD...
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving...
Teva Statement on European Commission Decision; Company to Appeal Teva Pharmaceuticals disagrees with the European Commission decision, which is based on legal theories that the company believes...
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara®...
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA Prolia® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture...
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate The expansion of the strategic partnership reinforces the solid foundation of the...
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S. This first-to-market launch showcases Teva’s...
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024 TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.999999 | -5.83089829918 | 17.149999 | 18.149999 | 15.95 | 14143 | 16.2188215 | DE |
| 4 | -0.55 | -3.29341317365 | 16.7 | 18.149999 | 15.95 | 11227 | 16.72731671 | DE |
| 12 | -0.3 | -1.82370820669 | 16.45 | 18.149999 | 15.5 | 10870 | 16.45018831 | DE |
| 26 | 1.05 | 6.95364238411 | 15.1 | 18.149999 | 13 | 13765 | 15.89767284 | DE |
| 52 | 8.09 | 100.372208437 | 8.06 | 18.149999 | 8 | 18485 | 13.08533957 | DE |
| 156 | 7.21 | 80.6487695749 | 8.94 | 18.149999 | 7.58 | 18110 | 12.47458955 | DE |
| 260 | 7.21 | 80.6487695749 | 8.94 | 18.149999 | 7.58 | 18110 | 12.47458955 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
